Citius Oncology, INC. (CTOR) — SEC Filings

Overview

Citius Oncology, INC. (CTOR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 23, 2025: Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on targeted oncology therapies, with its lead product LYMPHIR™ (denileukin diftitox) approved by the U.S. FDA in August 2024 and launched in December 2025 for persistent or recurrent CTCL. The company projects an underserved market

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Citius Oncology, INC. is neutral.

Filing Type Overview

Citius Oncology, INC. (CTOR) has filed 3 10-K, 27 8-K, 2 DEF 14A, 5 10-Q, 1 S-1/A, 1 10-K/A, 4 SC 13G/A, 1 8-K/A, 1 SC 13D/A, 3 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (48)

• Citius Oncology Launches LYMPHIR Amidst Going Concern Doubts — 10-K · Dec 23, 2025 Risk: high
  Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on targeted oncology therapies, with its lead product LYMPHIR™ (denileukin diftitox) approve
• Citius Oncology Files 8-K: Material Agreement, Equity Sales — 8-K · Dec 10, 2025 Risk: medium
  On December 8, 2025, Citius Oncology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
• Citius Oncology Files 8-K Report — 8-K · Dec 1, 2025 Risk: low
  On December 1, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial St
• Citius Oncology Files 8-K: Director Changes, Officer Comp, Shareholder Votes — 8-K · Oct 27, 2025 Risk: medium
  On October 27, 2025, Citius Oncology, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of
• Citius Oncology Files 8-K Report — 8-K · Oct 23, 2025 Risk: low
  On October 23, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Th
• CTOR Seeks Share Dilution, Board Re-election at Oct. 27 Meeting — DEF 14A · Sep 26, 2025 Risk: medium
  Citius Oncology, Inc. (CTOR) is holding its Annual Meeting on October 27, 2025, to address three key proposals. The company seeks to elect two Class I directors
• Citius Oncology Files 8-K: Equity Sale, Officer Changes, Financials — 8-K · Sep 19, 2025 Risk: medium
  On September 19, 2025, Citius Oncology, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The filing also announced the departure o
• Citius Oncology Files 8-K with Key Agreements and Disclosures — 8-K · Sep 10, 2025 Risk: medium
  On September 9, 2025, Citius Oncology, Inc. filed an 8-K report detailing several key events. The company entered into a Material Definitive Agreement, reported
• Citius Oncology Files 8-K Report — 8-K · Aug 18, 2025 Risk: medium
  On August 18, 2025, Citius Oncology, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is incorporate
• Citius Oncology's Losses Mount, Cash Dwindles Amid Going Concern Doubts — 10-Q · Aug 12, 2025 Risk: high
  Citius Oncology, Inc. (CTOR) reported a net loss of $19,764,713 for the nine months ended June 30, 2025, a significant increase from the $14,335,799 net loss fo
• Citius Oncology Files 8-K: Material Agreement and Other Events — 8-K · Jul 18, 2025 Risk: medium
  On July 16, 2025, Citius Oncology, Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements a
• Citius Oncology Amends S-1 for Continuous Offering — S-1/A · Jul 14, 2025 Risk: high
  CITIUS ONCOLOGY, INC. (CTOR) filed an S-1/A on July 14, 2025, as an amendment to its initial registration statement, indicating a proposed sale of securities on
• Citius Oncology Files 8-K: Other Events — 8-K · Jun 27, 2025 Risk: low
  On June 26, 2025, Citius Oncology, Inc. filed an 8-K report detailing an 'Other Events' filing. The company, formerly known as TenX Keane Acquisition until Marc
• Citius Oncology Files 8-K Report — 8-K · Jun 17, 2025 Risk: low
  On June 17, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company,
• Citius Oncology Files Q1 2025 10-Q Report — 10-Q · May 14, 2025 Risk: low
  Citius Oncology, Inc. filed its 10-Q for the quarterly period ended March 31, 2025. The company, formerly known as TenX Keane Acquisition, is incorporated in De
• Citius Oncology Faces Delisting Concerns — 8-K · Apr 25, 2025 Risk: high
  On April 23, 2025, Citius Oncology, Inc. filed an 8-K to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly know
• Citius Oncology Enters Material Definitive Agreement — 8-K · Apr 3, 2025 Risk: medium
  On March 28, 2025, Citius Oncology, Inc. entered into a material definitive agreement. The company, formerly known as TenX Keane Acquisition until March 15, 202
• Citius Oncology Files Q4 2024 10-Q Report — 10-Q · Feb 14, 2025 Risk: low
  Citius Oncology, Inc. filed its quarterly report on Form 10-Q for the period ended December 31, 2024. The company, previously known as TenX Keane Acquisition un
• Citius Oncology Files 8-K Report — 8-K · Feb 6, 2025 Risk: low
  On February 6, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The compan
• Citius Oncology Files 10-K/A Amendment — 10-K/A · Jan 27, 2025 Risk: medium
  CITIUS ONCOLOGY, INC. filed an amendment (10-K/A) to its annual report for the fiscal year ended September 30, 2024. The filing, dated January 27, 2025, provide
• Citius Oncology Files 8-K Report — 8-K · Jan 7, 2025 Risk: low
  On January 7, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company
• Citius Oncology Files 8-K Report — 8-K · Jan 6, 2025 Risk: low
  On January 6, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific
• CITIUS ONCOLOGY, INC. Files 2024 Annual Report — 10-K · Dec 27, 2024 Risk: low
  CITIUS ONCOLOGY, INC. filed its annual report for the fiscal year ended September 30, 2024. The company, formerly known as TenX Keane Acquisition until March 15
• Citius Oncology Files 8-K Report — 8-K · Nov 12, 2024 Risk: low
  On November 11, 2024, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specif
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• Citius Oncology Enters Material Definitive Agreement — 8-K · Sep 13, 2024 Risk: medium
  On September 9, 2024, Citius Oncology, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, the ot
• Citius Oncology Files 8-K Report — 8-K · Sep 5, 2024 Risk: low
  On September 5, 2024, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
• SC 13G/A Filing — SC 13G/A · Sep 5, 2024
• Cituis Oncology Files 8-K/A Amendment on Asset Acquisition — 8-K/A · Aug 26, 2024 Risk: low
  Cituis Oncology, Inc. filed an amendment (8-K/A) on August 26, 2024, to its Form 8-K dated August 12, 2024. This amendment pertains to the completion of an acqu
• CITIUS ONCOLOGY (CTSO) Files 8-K: Acquisition, Equity Sales, Accountant Change — 8-K · Aug 16, 2024 Risk: medium
  On August 12, 2024, Citius Oncology, Inc. (formerly TenX Keane Acquisition) filed an 8-K detailing several significant events. These include entering into a mat
• 10XYZ Holdings LP Amends Citius Oncology Filing — SC 13D/A · Aug 15, 2024 Risk: medium
  10XYZ Holdings LP, formerly known as TenX Keane Acquisition, has filed an amendment (SC 13D/A) on August 15, 2024, regarding their holdings in Citius Oncology,
• CITIUS ONCOLOGY Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  CITIUS ONCOLOGY, INC. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as TenX Keane Acquisition, is in the pharmaceutical prepar
• TenX Keane Acquisition Combines with 03 Life Sciences — 8-K · Aug 5, 2024 Risk: medium
  On August 2, 2024, TenX Keane Acquisition announced a significant business combination with 03 Life Sciences, a pharmaceutical preparations company. The filing
• TenX Keane Acquisition Signs Material Definitive Agreement — 8-K · Jul 19, 2024 Risk: medium
  On July 17, 2024, TenX Keane Acquisition entered into a material definitive agreement related to its business combination. The company, incorporated in the Caym
• TenX Keane Acquisition Enters Material Agreement — 8-K · Jun 18, 2024 Risk: medium
  On June 17, 2024, TenX Keane Acquisition entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation
• TenX Keane Acquisition Files 8-K — 8-K · Jun 6, 2024 Risk: low
  On May 31, 2024, TenX Keane Acquisition filed an 8-K report detailing other events. The company, incorporated in the Cayman Islands, is involved in the pharmace
• TenX Keane Acquisition Enters Material Definitive Agreement — 8-K · May 21, 2024 Risk: medium
  On May 17, 2024, TenX Keane Acquisition entered into a material definitive agreement, likely related to its business as a pharmaceutical preparations company. T
• TenX Keane Acquisition Files Q1 2024 10-Q — 10-Q · May 20, 2024 Risk: low
  TenX Keane Acquisition filed its 10-Q for the period ending March 31, 2024. The company, operating in pharmaceutical preparations, reported its financial status
• TenX Keane Acquisition Signs Material Definitive Agreement — 8-K · Apr 29, 2024 Risk: medium
  On April 26, 2024, TenX Keane Acquisition entered into a material definitive agreement related to its business. The company, incorporated in the Cayman Islands,
• TenX Keane Acquisition Files 2023 Annual Report on Form 10-K — 10-K · Apr 16, 2024 Risk: low
  TenX Keane Acquisition (CTOR) filed a Annual Report (10-K) with the SEC on April 16, 2024. TenX Keane Acquisition filed its annual report for the fiscal year en
• SC 13G/A Filing — SC 13G/A · Mar 7, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• Wolverine Asset Management Takes 5.0% Passive Stake in TenX Keane — SC 13G · Feb 8, 2024 Risk: low
  Wolverine Asset Management, LLC, a Chicago-based investment firm, reported owning 5.0% of TenX Keane Acquisition's Ordinary Shares as of December 31, 2023. This
• Space Summit Capital Divests Entire Stake in TenX Keane Acquisition — SC 13G/A · Feb 5, 2024
  Space Summit Capital LLC, a Delaware-based entity, filed an amended SC 13G/A on February 5, 2024, indicating they no longer beneficially own any shares of TenX
• TenX Keane Acquisition Reports Capital Structure Changes — 8-K · Jan 18, 2024
  TenX Keane Acquisition filed an 8-K on January 18, 2024, reporting an event on January 17, 2024, related to its corporate structure. The filing indicates change
• TenX Keane Acquisition Updates Business Address in 8-K Filing — 8-K · Jan 10, 2024
  TenX Keane Acquisition, a SPAC, filed an 8-K on January 10, 2024, to update its business address to 420 Lexington Ave, Suite 2446, New York, NY 10170. This admi
• TenX Keane Acquisition Calls Extraordinary General Meeting for January 17, 2024 — DEF 14A · Jan 8, 2024 Risk:
  TenX Keane Acquisition (CTOR) filed a Proxy Statement (DEF 14A) with the SEC on January 8, 2024. TenX Keane Acquisition will hold an extraordinary general meeti

Risk Profile

Risk Assessment: Of CTOR's 39 recent filings, 4 were flagged as high-risk, 18 as medium-risk, and 17 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Myron Holubiak
• Joel Mayersohn
• Leonard Mazur
• Jaime Bartushak
• Lorna A. Knick, Esq.
• Alexander M. Donaldson, Esq.
• Christopher P. Agoranos, Esq.
• Mark E. Crone, Esq.
• Taylor Zhang
• David Chen
• Jian Li
• Christopher L. Gust
• Robert R. Bellick

Industry Context

Citius Oncology operates in the biopharmaceutical sector, specifically focusing on targeted oncology therapies. The market for rare cancer treatments like CTCL is often underserved, presenting opportunities for companies with innovative therapies. However, the industry is highly competitive, with significant R&D costs, long development cycles, and stringent regulatory hurdles.

Top Tags

material-agreement (6) · financials (5) · 8-k (5) · 8-K (5) · pharmaceuticals (5) · sec-filing (5) · corporate-filing (4) · 10-Q (4) · Biotechnology (3) · Oncology (3)

Key Numbers

• Estimated market for LYMPHIR: $400M — Underserved market that Citius Oncology aims to capture
• FDA approval date for LYMPHIR: August 2024 — Key regulatory milestone for the lead product
• LYMPHIR launch date: December 2025 — Commercialization start for the lead product
• Citius Pharma's ownership stake: 77.9% — As of December 17, 2025, indicating Citius Oncology is a controlled company
• Objective Response Rate (ORR): 25/69 — Number of responders out of subjects in the Phase 3 trial for Stage I-III CTCL
• Market value of non-affiliate common equity: $5,097,850 — As of March 31, 2025, indicating a relatively small public float
• Shares outstanding: 84,797,846 — As of December 23, 2025
• SEC File Number: 001-41534 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 99-4362660 — Company's tax identification number.
• Proposed shares reserved under 2024 Omnibus Stock Incentive Plan: 30,000,000 — Increase from current 15,000,000 shares, representing a 100% increase
• Current shares reserved under 2024 Omnibus Stock Incentive Plan: 15,000,000 — Baseline before proposed amendment
• Shares of common stock outstanding: 83,513,442 — As of record date September 19, 2025, entitled to vote
• Date of Annual Meeting of Stockholders: October 27, 2025 — Key date for voting on proposals
• Record date for Annual Meeting: September 19, 2025 — Determines stockholders eligible to vote
• Year Class I directors' term expires: 2028 — If Myron Holubiak and Joel Mayersohn are elected

Forward-Looking Statements

• {"claim":"TenX Keane Acquisition's stock may see increased investor interest due to institutional backing.","entity":"TenX Keane Acquisition","targetDate":"Q2 2024","confidence":"medium"}
• {"claim":"Wolverine Asset Management will maintain a passive investment stance.","entity":"Wolverine Asset Management, LLC","targetDate":"Q4 2024","confidence":"high"}

Related Companies

CTXR · BIOS · ASMB · CTZX · CTSO · CTOS

Frequently Asked Questions